News DiPersio

DiPersio leads 1st US clinical trial with ApoGraf to prevent GvHD

View Content

Dr. John DiPersio (Department of Medicine, Chief, Division of Oncology) will lead the first US Phase I/II clinical trial for ApoGraf, a stem cell selection technology developed by Cellect Biotechnology. ApoGraf is designed to prevent acute Graft vs. Host Disease following bone marrow transplant.